#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 449
Sodium Chloride 415
Carboplatin 338
Cisplatin 282
Paclitaxel 251
Fluorouracil 232
Oxaliplatin 223
Nivolumab 210
Dexamethasone 205
Rituximab 194
Cyclophosphamide 187
Durvalumab 162
Bevacizumab 161
Capecitabine 157
Paracetamol 156
Atezolizumab 145
Docetaxel 128
Prednisone 127
Tocilizumab 125
Prednisolone 121
Gemcitabine 117
Venetoclax 116
Mycophenolate Mofetil 115
Pemetrexed 114
Etoposide 114
Doxorubicin Hydrochloride 109
Infliximab 99
Lenalidomide 98
Ipilimumab 90
Semaglutide 90
Folinic Acid 89
Acetylsalicylic Acid 88
Placebo 85
Paclitaxel Albumin-Bound 84
Daratumumab 79
Cytarabine 79
Calcium Folinate 78
Methotrexate 78
Fludarabine Phosphate 77
Letrozole 72
Bortezomib 72
Olaparib 70
Gemcitabine Hydrochloride 69
Dapagliflozin 68
Obinutuzumab 67
Azacitidine 66
Trastuzumab 65
Tacrolimus 63
Cetuximab 63
Lenvatinib 62
Fulvestrant 62
Methylprednisolone 61
Irinotecan 61
Irinotecan Hydrochloride Trihydrate 59
Temozolomide 59
Cemiplimab 57
Vincristine Sulfate 57
Trastuzumab Deruxtecan 53
Apixaban 51
Enzalutamide 51
Betamethasone Sodium Phosphate 50
Lidocaine Hydrochloride Monohydrate 50
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 49
Amoxicillin 47
Buclizine Hydrochloride 47
Lidocaine Hydrochloride 47
Exemestane 46
Potassium Chloride 46
Empagliflozin 46
Hydrocortisone 45
Anastrozole 45
Adalimumab 45
Ribociclib 44
Pomalidomide 43
Pertuzumab 43
Doxorubicin 43
Clavulanic Acid 42
Oxygen 42
Clopidogrel 42
Rivaroxaban 41
Ibrutinib 41
Tenofovir Alafenamide 41
Ruxolitinib 41
Ropivacaine Hydrochloride 40
Abemaciclib 40
Atorvastatin 40
Trimethoprim 39
Metformin Hydrochloride 39
Bendamustine Hydrochloride 39
Carfilzomib 39
Cyclophosphamide Monohydrate 39
Sulfamethoxazole 39
Palbociclib 38
Linezolid 38
Ifosfamide 38
Pemetrexed Disodium 38
Propofol 38
Dostarlimab 37
Acalabrutinib 37

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

4 weeks ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

4 weeks ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

4 weeks ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

4 weeks ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

4 weeks ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

4 weeks ago

All drugs

  • 2 

    Bexmarilimab

    , ,

    Bexmarilimab, an innovative drug targeting the CLEVER-1 protein, is currently being studied in clinical trials for various types of cancer. These trials aim to assess its safety, tolerability, and potential effectiveness when used alone or in combination with other treatments. The studies focus on different cancer types, including renal cell carcinoma, colon cancer, non-small cell lung cancer, and hematological malignancies, offering hope for new treatment options in oncology.

    Related diseases and areas:

  • 1 

    Bexotegrast

    ,

    Bexotegrast, also known as PLN-74809, is an innovative drug currently being studied in clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). This article explores the ongoing research into Bexotegrast’s potential to improve lung function and quality of life for patients with this challenging respiratory condition.

    Related diseases and areas:

  • 5 

    Bezafibrate

    , ,

    Bezafibrate, a medication primarily used to treat high cholesterol and triglyceride levels, has been the subject of several clinical trials exploring its potential benefits in various medical conditions. These trials aim to investigate the drug’s efficacy and safety in treating disorders such as mitochondrial diseases, bipolar depression, and liver conditions like primary biliary cholangitis. This article summarizes the key findings from recent clinical trials involving bezafibrate and its potential applications beyond its traditional use.

    Related diseases and areas:

  • 1 

    Bgb-15025 Citrate

    ,

    This article discusses the ongoing clinical trials of BGB-15025 Citrate, a promising drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC). The trials aim to evaluate the effectiveness and safety of BGB-15025 Citrate in combination with other investigational agents and chemotherapy for patients with previously untreated, locally advanced, unresectable, or metastatic NSCLC.

    Related diseases and areas:

  • 3 

    BGB-16673

    ,

    BGB-16673 is an innovative drug currently being studied in clinical trials for various conditions, primarily B-cell malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It works as a Bruton tyrosine kinase (BTK)-targeted protein degrader, representing a new approach to treating these conditions. The drug is also being investigated for chronic spontaneous urticaria (CSU), showing potential across different therapeutic areas. Clinical trials are evaluating BGB-16673’s safety, effectiveness, appropriate dosing, and comparing it to existing treatments to determine its place in treatment protocols.

    Related diseases and areas:

  • 1 

    Bgb-A445

    ,

    BGB-A445 is an investigational drug currently being studied in clinical trials for the treatment of various advanced solid tumors. This article will provide an overview of the ongoing research, potential benefits, and key information about BGB-A445 in combination with other therapies for patients with advanced cancers.

    Related diseases and areas:

  • 4 

    Bhv-7000

    ,

    BHV-7000 is an investigational drug currently being studied in clinical trials for various neurological and psychiatric conditions. These trials aim to evaluate the safety, tolerability, and efficacy of BHV-7000 in treating refractory focal epilepsy, idiopathic generalized epilepsy, bipolar disorder, and major depressive disorder. The studies involve different dosages and treatment durations to determine the optimal use of this potential new medication.

    Related diseases and areas:

  • 7 

    Bi 1015550

    , ,

    BI 1015550, also known as Nerandomilast, is a drug currently being studied in various clinical trials. These trials aim to investigate its safety, tolerability, and how it’s processed in the body (pharmacokinetics) in different populations, including healthy volunteers and those with specific health conditions. The studies explore different dosages, formulations, and administration methods to better understand the drug’s potential therapeutic use.

    Related diseases and areas:

  • 4 

    Bi 1291583

    ,

    Clinical trials are currently underway to investigate the potential of BI 1291583, a new drug being studied for its effects on bronchiectasis and cystic fibrosis bronchiectasis. These trials aim to assess the drug’s safety, tolerability, and effectiveness in treating these respiratory conditions. The studies involve various formulations and dosages of BI 1291583, as well as examining how the drug is processed in the body. This article summarizes the key findings from these ongoing clinical trials.

    Related diseases and areas:

  • 1 

    Bi 1819479

    ,

    BI 1819479 is an investigational drug currently being studied in clinical trials for its potential to treat Idiopathic Pulmonary Fibrosis (IPF), a serious lung condition. These trials aim to evaluate the drug’s safety, effectiveness, and how it’s processed in the body. Researchers are conducting studies with both healthy volunteers and IPF patients to gather comprehensive data on this promising new medication.

    Related diseases and areas:

  • 1 

    Bi 1839100

    ,

    BI 1839100 is a new drug being studied in clinical trials for its potential in treating pulmonary fibrosis and associated chronic cough. These trials aim to assess the safety, tolerability, and effectiveness of BI 1839100 in healthy individuals and patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). The studies range from initial safety assessments in healthy volunteers to more advanced trials evaluating the drug’s impact on cough frequency and lung function in patients with pulmonary fibrosis.

    Related diseases and areas:

  • 0 

    Bi 3032950

    ,

    BI 3032950 is an investigational drug currently being studied in clinical trials for its potential in treating ulcerative colitis and its safety profile in healthy individuals. These trials aim to evaluate the drug’s effectiveness, safety, and how it behaves in the body when administered through different methods, including intravenous infusion and subcutaneous injection.

    Related diseases and areas:

  • 2 

    Bi 3720931

    ,

    This article explores the clinical trials of BI 3720931, an innovative inhaled lentiviral vector gene therapy for cystic fibrosis (CF) patients who are ineligible for CFTR modulators. The trials aim to assess the safety, tolerability, and efficacy of this new treatment, offering hope for improved lung function and quality of life for individuals with CF. We’ll delve into the key aspects of these trials, including their objectives, eligibility criteria, and potential outcomes.

    Related diseases and areas:

  • 5 

    BI 456906

    ,

    BI 456906, also called survodutide, is a medicine being studied in clinical trials for conditions linked to body weight and metabolism. Trials are looking at how it helps with weight loss, how it affects blood sugar in type 2 diabetes, and how safe it is for the heart and kidneys. Other studies focus on how the body absorbs the drug, and how liver or kidney problems may change drug levels in the blood.

    Related diseases and areas:

  • 3 

    Bi 685509

    , ,

    Avenciguat, also known as BI 685509, is an investigational drug being studied in clinical trials for various conditions, including diabetic kidney disease, liver cirrhosis with portal hypertension, and systemic sclerosis. These trials aim to evaluate the safety, tolerability, and efficacy of Avenciguat in treating these complex medical conditions.

    Related diseases and areas:

  • 5 

    Bi 690517

    , , , ,

    BI 690517, also known as Vicadrostat, is an investigational drug currently being studied in various clinical trials. These trials aim to evaluate its safety, efficacy, and potential benefits in treating chronic kidney disease, particularly in patients with diabetic nephropathy. The studies explore how the drug is absorbed and processed by the body, its effects on kidney function, and its potential to slow the progression of kidney disease when used alone or in combination with other medications.

    Related diseases and areas:

  • 1 

    Bi 706321

    ,

    BI 706321 is an experimental drug currently being studied in clinical trials for its potential in treating Crohn’s disease. These trials aim to evaluate the safety, tolerability, and effectiveness of BI 706321 when used alone or in combination with other medications. The studies involve healthy volunteers and patients with Crohn’s disease, providing valuable insights into how the drug works in different populations and conditions.

    Related diseases and areas:

  • 1 

    Bi 764524

    ,

    BI 764524 is an investigational drug currently being studied in clinical trials for the treatment of diabetic retinopathy, a serious eye condition affecting people with diabetes. These trials aim to evaluate the safety, tolerability, and effectiveness of BI 764524 in patients with various stages of diabetic retinopathy, including those who have undergone laser treatment and those with non-proliferative diabetic retinopathy.

    Related diseases and areas:

  • 1 

    Bi 764532

    , ,

    BI 764532, also known as Obrixtamig, is an innovative antibody-like molecule being studied in clinical trials for various advanced cancers, including small cell lung cancer, neuroendocrine tumors, and gliomas. This drug is designed to help the immune system fight cancer by targeting a tumor marker called DLL3. The ongoing trials aim to determine the optimal dosage, safety profile, and effectiveness of BI 764532 when used alone or in combination with other treatments.

    Related diseases and areas:

  • 1 

    Bi 765845

    ,

    BI 765845 is a new medication currently being studied in clinical trials to help people who have recently experienced a heart attack. These trials aim to evaluate the drug’s effectiveness, safety, and how well it is tolerated by patients. The studies involve both heart attack patients and healthy volunteers to gather comprehensive data on the drug’s potential benefits and side effects.

    Related diseases and areas:

  • 1 

    BI-1607

    ,

    BI-1607 is a promising new drug being investigated for patients with HER2-positive cancers, including breast cancer and gastric cancer. This monoclonal antibody targets CD32b (Fc Gamma Receptor IIB) and is designed to enhance the effectiveness of trastuzumab (Herceptin), a standard treatment for HER2-positive cancers. While trastuzumab has significantly improved survival rates, many patients develop resistance over time, leading to disease progression. Clinical trials are currently underway to evaluate how BI-1607, when combined with trastuzumab, might overcome this resistance and improve outcomes for patients whose cancers have progressed after standard therapy.

    Related diseases and areas:

  • 1 

    Bi-1808

    ,

    A groundbreaking clinical trial is underway to assess the safety and efficacy of BI-1808, a new monoclonal antibody targeting TNFR2, in patients with advanced malignancies. This study aims to explore BI-1808 both as a standalone treatment and in combination with pembrolizumab (KEYTRUDA®), a well-known immunotherapy drug. The trial seeks to determine the optimal dosage and potential benefits for patients whose cancer has progressed despite standard treatments.

    Related diseases and areas:

  • 1 

    Bi-1910

    ,

    A groundbreaking clinical trial is underway to evaluate the effectiveness and safety of BI-1910, a new drug designed to target advanced solid tumors. This study aims to assess BI-1910 both as a standalone treatment and in combination with pembrolizumab, a known immunotherapy drug. The trial focuses on patients with advanced or metastatic solid tumors, including non-small cell lung cancer and hepatocellular carcinoma, whose conditions have not improved with standard treatments. This research could potentially open new doors for cancer treatment, offering hope to patients with limited options.

    Related diseases and areas:

  • 11 

    Bicalutamide

    , ,

    Bicalutamide, also known by its brand name Casodex, is a drug that has been the subject of various clinical trials for its potential in treating different types of cancer. These trials primarily focus on prostate cancer and certain breast cancers, exploring the drug’s effectiveness, safety, and impact on patients’ quality of life. The studies range from bioequivalence tests to combination therapies with other drugs, providing valuable insights into the role of bicalutamide in cancer treatment.

    Related diseases and areas:

  • 19 

    Bictegravir

    , ,

    Bictegravir is a novel antiretroviral medication being studied in clinical trials for the treatment of HIV-1 infection. As part of a single-tablet regimen combined with emtricitabine and tenofovir alafenamide (B/F/TAF), bictegravir shows promise in providing effective, well-tolerated treatment for diverse populations of people living with HIV. This article summarizes key findings from recent clinical trials evaluating bictegravir-based regimens.

    Related diseases and areas:

  • 1 

    Bidridistrogene Xeboparvovec

    ,

    Bidridistrogene Xeboparvovec, also known as SRP-9003, is an investigational gene therapy being studied for the treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (LGMD2E/R4). This article discusses the ongoing clinical trials evaluating the safety and effectiveness of this promising therapy for patients with this rare genetic muscle disorder.

    Related diseases and areas:

  • 8 

    Bifikafusp Alfa

    , ,

    This article summarizes several clinical trials investigating the use of Bifikafusp Alfa, also known as L19IL2 or Darleukin, for treating different types of skin cancers. These trials are exploring the drug’s effectiveness when injected directly into tumors, either alone or in combination with other treatments. The studies focus on patients with advanced melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin cancers that are difficult to treat with standard methods.

    Related diseases and areas:

  • 1 

    BIIB115

    ,

    Researchers are currently studying a medication called BIIB115 for potential use in treating spinal muscular atrophy (SMA), particularly in children who have previously received gene therapy. This clinical trial is designed to evaluate the safety, tolerability, and how the drug moves through the body in both healthy adult males and children with SMA. The study is divided into two parts: Part A involves healthy volunteers receiving a single dose of either BIIB115 or placebo, while Part B focuses on children with SMA who previously received onasemnogene abeparvovec (Zolgensma™) gene therapy. This research aims to provide important insights into how BIIB115 might benefit patients with SMA and establish appropriate dosing guidelines for potential future treatments.

    Related diseases and areas:

  • 3 

    Bilastine

    ,

    Bilastine is an antihistamine medication that has been the subject of numerous clinical trials investigating its use in various allergic conditions. These trials have explored different formulations, dosages, and applications of bilastine, ranging from oral tablets to ophthalmic solutions. The studies have focused on assessing the drug’s efficacy, safety, and tolerability in treating conditions such as allergic rhinitis, urticaria, and allergic conjunctivitis across different age groups.

    Related diseases and areas:

  • 4 

    Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts

    ,

    Clinical trials are underway to evaluate the safety and effectiveness of a new skin graft treatment called EHSG-KF (also known as denovoSkin™). This innovative therapy uses a bilayer engineered collagen hydrogel-based skin graft composed of a patient’s own (autologous) keratinocytes and fibroblasts. The trials aim to compare EHSG-KF to standard split-thickness skin grafts (STSG) for treating deep partial and full-thickness burns, as well as other full-thickness skin defects in both adults and children.

    Related diseases and areas:

  • 5 

    Bimatoprost

    , , ,

    Bimatoprost is a medication that has been the subject of numerous clinical trials, primarily focusing on its effectiveness in treating glaucoma and ocular hypertension. These studies have explored various formulations and applications of bimatoprost, including eye drops, ocular inserts, and even its potential use for conditions like eyebrow hypotrichosis and androgenetic alopecia. This article summarizes key findings from recent clinical trials investigating bimatoprost’s safety, efficacy, and potential new uses.

    Related diseases and areas:

  • 13 

    Bimekizumab

    , , ,

    Bimekizumab is an investigational biologic medication being studied in clinical trials for the treatment of various autoimmune conditions. This article summarizes key information about ongoing clinical trials evaluating bimekizumab’s safety, efficacy, and administration methods for conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

    Related diseases and areas:

  • 14 

    Binimetinib

    , ,

    Binimetinib is an innovative drug being studied in clinical trials for treating several types of cancer. This article summarizes key information about ongoing research into binimetinib’s potential as a cancer therapy, including its mechanisms, target cancers, and early results from clinical studies.

    Related diseases and areas:

  • 2 

    Bintrafusp Alfa

    , ,

    Bintrafusp alfa, also known as M7824, is an innovative drug being studied in clinical trials for the treatment of various types of cancer. This bifunctional fusion protein targets both TGF-β and PD-L1, showing potential in combating advanced and difficult-to-treat cancers. Clinical trials are investigating its efficacy and safety in cancers such as urothelial carcinoma, mesothelioma, cervical cancer, and more.

    Related diseases and areas:

  • 3 

    Bio89-100

    ,

    BIO89-100, also known as Pegozafermin, is an investigational drug currently being studied in clinical trials for the treatment of Nonalcoholic Steatohepatitis (NASH). These trials aim to evaluate the safety, efficacy, and tolerability of BIO89-100 in patients with NASH, including those with compensated cirrhosis. The drug is administered through subcutaneous injections and shows potential in addressing various aspects of NASH, including liver health and metabolic factors.

    Related diseases and areas:

  • 4 

    Biotin

    , , , ,

    Biotin, also known as vitamin B7, is being studied in clinical trials for its potential benefits in various medical conditions. These trials aim to investigate biotin’s effects on red blood cell survival, anemia, multiple sclerosis, Huntington’s disease, and cancer detection. Researchers are exploring different applications of biotin, from its use as a marker in blood cells to its potential therapeutic effects when combined with other substances.

    Related diseases and areas:

  • 1 

    Birtamimab

    ,

    A groundbreaking clinical trial is underway to assess the effectiveness and safety of a new drug called Birtamimab in patients with advanced Light Chain (AL) Amyloidosis. This study focuses on individuals classified as Mayo Stage IV, the most severe stage of the disease. The trial aims to determine if Birtamimab, when combined with standard care, can improve survival rates and quality of life for these critically ill patients.

    Related diseases and areas:

  • 3 

    Bisacodyl

    , ,

    This article summarizes several clinical trials investigating the use of bisacodyl, a stimulant laxative, for treating constipation and improving bowel motility. Researchers have studied bisacodyl’s effects in various patient populations, including those with chronic constipation, multiple sclerosis, and post-surgical patients. The trials examine bisacodyl’s efficacy, safety, and impact on quality of life compared to placebos and other treatments.

    Related diseases and areas:

  • 5 

    Bisoprolol

    ,

    This article examines the use of Bisoprolol, a beta-blocker medication, in various clinical trials. These studies investigate Bisoprolol’s effectiveness and safety in treating conditions such as hypertension, atrial fibrillation after heart surgery, and its bioequivalence with other formulations. The trials provide valuable insights into Bisoprolol’s role in managing cardiovascular health.

    Related diseases and areas:

  • 12 

    Bisoprolol Fumarate

    , ,

    Bisoprolol Fumarate is a beta-blocker medication that has been the subject of several clinical trials investigating its effectiveness in treating various cardiovascular conditions. This article summarizes key findings from recent studies exploring the use of Bisoprolol Fumarate in conditions such as hypertension, acute coronary syndrome, and heart failure. We’ll examine how this drug performs in different patient populations and its potential benefits and side effects.

    Related diseases and areas:

  • 1 

    Bispecific Protein With A High-Affinity T-Cell Receptor Domain Fused To An Antibody Single-Chain Variable Fragment Against Cd3

    ,

    A groundbreaking clinical trial is underway to evaluate IMC-M113V, a new bispecific protein designed to target chronic HIV infection. This innovative treatment combines a high-affinity T-cell receptor domain with an antibody fragment against CD3, potentially offering a new approach for patients with suppressed viral loads. The study aims to assess the safety, effectiveness, and potential for long-term viral control in HIV-positive individuals who are currently on antiretroviral therapy.

    Related diseases and areas:

  • 5 

    Bjt-778

    ,

    A groundbreaking clinical trial is underway to assess the potential of BJT-778, a new drug developed for patients with chronic hepatitis B and D infections. This Phase 1/2a study aims to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of BJT-778 in both healthy volunteers and individuals with chronic hepatitis B, including those with chronic hepatitis D infection. The trial represents a significant step forward in the search for effective treatments for these persistent viral infections.

    Related diseases and areas:

  • 12 

    Bleomycin

    , ,

    Bleomycin, a potent antineoplastic drug, is being extensively studied in various clinical trials for its potential in treating different types of cancers and vascular malformations. This article explores the latest research on Bleomycin’s applications, efficacy, and safety across multiple medical conditions, highlighting its versatility in modern cancer therapy.

    Related diseases and areas:

  • 6 

    Bleomycin Sulfate

    , ,

    Bleomycin sulfate, a powerful antineoplastic drug, is being studied in various clinical trials to explore its potential in treating different medical conditions. These trials aim to evaluate the efficacy and safety of bleomycin sulfate in treating cutaneous warts, venous malformations, lymphatic malformations, and as part of combination therapies for cancers like Hodgkin’s lymphoma and Kaposi’s sarcoma. The research focuses on optimizing dosages, comparing bleomycin to other treatments, and investigating its use in combination with other drugs to improve patient outcomes.

    Related diseases and areas:

  • 3 

    Bleomycin Sulfate Ph. Eur.

    , , , ,

    This article discusses two clinical trials investigating the use of Bleomycin Sulfate Ph. Eur., a medication primarily used in cancer treatment. The first trial examines the effects of various cancer treatments, including Bleomycin, on speech perception, cognition, and quality of life in patients with different types of cancer. The second trial focuses on using Bleomycin in sclerotherapy for treating Warthin’s tumor, a benign salivary gland tumor. These studies aim to improve our understanding of Bleomycin’s efficacy and potential side effects in different medical contexts.

    Related diseases and areas:

  • 4 

    BLEXIMENIB

    ,

    BLEXIMENIB (also known as JNJ-75276617) is a promising new drug currently being investigated in clinical trials for the treatment of acute leukemia, including Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). This oral medication works as a Menin-KMT2A (MLL1) inhibitor, targeting specific genetic alterations found in certain leukemia patients. Multiple clinical trials are currently exploring BLEXIMENIB’s effectiveness both as a standalone treatment and in combination with other established leukemia therapies such as Venetoclax, Azacitidine, and standard chemotherapy regimens. These trials aim to determine the appropriate dosing, safety profile, and effectiveness of BLEXIMENIB in various patient populations, from newly diagnosed to those with relapsed or refractory disease.

    Related diseases and areas:

  • 21 

    Blinatumomab

    , , ,

    Blinatumomab is an innovative drug being studied in clinical trials for the treatment of acute lymphoblastic leukemia (ALL), a type of blood cancer. This article explores the use of blinatumomab in various clinical trials, its potential benefits, and its impact on patients with different forms of ALL, including those with minimal residual disease (MRD) and relapsed/refractory cases.

    Related diseases and areas:

  • 2 

    Blomia Tropicalis

    ,

    This article discusses a clinical trial investigating the use of Blomia tropicalis allergenic extract in skin prick tests for diagnosing mite allergies. The study aims to standardize the biological activity of various mite extracts, including Blomia tropicalis, to improve allergy diagnosis and treatment.

    Related diseases and areas:

  • 1 

    Blood And Related Products

    This article explores a clinical trial investigating the use of andexanet alfa, a drug designed to reverse the anticoagulation effects of factor Xa inhibitors in patients requiring urgent surgery. The study aims to assess the safety and effectiveness of andexanet alfa compared to usual care in reducing bleeding risk during surgical procedures for patients taking anticoagulants like apixaban, rivaroxaban, or edoxaban.

    Related diseases and areas:

  • 1 

    Blu-222

    ,

    BLU-222 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, focusing on the safety, effectiveness, and potential benefits of BLU-222 in treating various types of cancer, including breast cancer, ovarian cancer, and other solid tumors.

    Related diseases and areas:

  • 1 

    Blu-263 Phosphate

    ,

    Elenestinib (BLU-263) is an investigational drug being studied in clinical trials for the treatment of various forms of systemic mastocytosis, a rare blood disorder characterized by the abnormal accumulation of mast cells in different organs. These trials aim to evaluate the safety, efficacy, and optimal dosing of elenestinib in patients with advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM), as well as its potential use in combination with other therapies.

    Related diseases and areas:

  • 1 

    Blu-451

    ,

    BLU-451 is an innovative drug being studied in clinical trials for patients with advanced cancers, particularly those with EGFR Exon 20 insertion mutations. This article explores the ongoing research into BLU-451’s safety, effectiveness, and potential benefits for patients with specific types of lung cancer and other related conditions.

    Related diseases and areas:

  • 1 

    Bms-986288

    ,

    This article explores the ongoing clinical trials of BMS-986288, a novel immunotherapy drug being studied for the treatment of advanced solid cancers. The research aims to evaluate the safety and effectiveness of BMS-986288 when used alone and in combination with other drugs, particularly Nivolumab. This groundbreaking study offers hope for patients with advanced malignant tumors who may benefit from innovative treatment approaches.

    Related diseases and areas:

  • 1 

    Bms-986315

    ,

    This article discusses a clinical trial investigating the use of BMS-986315, a novel drug, in combination with nivolumab and chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). The study aims to assess the effectiveness and safety of this combination therapy compared to standard treatment approaches in patients with stage IV or recurrent NSCLC.

    Related diseases and areas:

  • 1 

    Bms-986340

    ,

    BMS-986340 is an investigational drug currently being studied in clinical trials for the treatment of various advanced solid tumors. This article provides an overview of the ongoing research, focusing on its potential as a monotherapy and in combination with other drugs like nivolumab and docetaxel. The study aims to assess the safety, tolerability, and recommended dosage of BMS-986340 in patients with different types of cancer, including lung, gastric, colorectal, and head and neck cancers, among others.

    Related diseases and areas:

  • 2 

    BMS-986365

    , ,

    BMS-986365 (also known as CC-94676) is an investigational drug currently being studied in various clinical trials to evaluate its safety, efficacy, and pharmacological properties. The clinical trials range from early Phase 1 studies in healthy volunteers to advanced Phase 3 trials in patients with metastatic castration-resistant prostate cancer (mCRPC). These studies aim to understand how the drug works in the body, how it’s processed, and most importantly, how it compares to existing treatments for prostate cancer. The research is designed to provide crucial information about proper dosing, potential side effects, and the overall benefit-risk profile of BMS-986365 before it can be considered for wider use in patient care.

    Related diseases and areas:

  • 1 

    Bms-986408

    ,

    A groundbreaking clinical trial is underway to evaluate the potential of BMS-986408, a novel drug being studied for the treatment of advanced solid tumors. This phase 1/2 study aims to assess the safety and effectiveness of BMS-986408 when used alone or in combination with other cancer treatments. The trial explores various treatment combinations and seeks to determine the optimal dosage for future studies, offering hope for patients with advanced solid tumors.

    Related diseases and areas:

  • 2 

    Bms-986435

    ,

    BMS-986435, also known as MYK-224, is an investigational drug currently being studied in clinical trials. These trials aim to evaluate its safety, effectiveness, and potential benefits for patients with heart conditions, particularly those with Heart Failure with Preserved Ejection Fraction (HFpEF). The studies involve healthy volunteers and patients, focusing on understanding how the drug behaves in the body and its effects on heart function.

    Related diseases and areas:

  • 1 

    Bms-986442

    ,

    BMS-986442, also known as AGEN1777, is an investigational drug being studied in clinical trials for the treatment of advanced solid tumors and non-small cell lung cancer. This article explores the ongoing research on BMS-986442 in combination with other therapies, providing insights into its potential benefits and the current state of clinical trials.

    Related diseases and areas:

  • 1 

    Bms-986449-03

    ,

    BMS-986449-03 is an investigational drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, including the drug’s potential benefits, side effects, and eligibility criteria for participation in the trials. The information presented is based on a Phase 1/2 study combining BMS-986449 with nivolumab, aimed at evaluating its safety and effectiveness in treating various types of advanced cancer.

    Related diseases and areas: